Expression of PD-1 and its ligands
The PD-1 (CD279) (see Glossary) receptor can be detected at the cell surface of T cells during thymic development and in the periphery of several types of hematopoietic cell following T cell receptor (TCR) signaling and cytokine stimulation. PD-1 is expressed on CD4 À
CD8
À thymocytes and inducibly expressed on peripheral CD4 + and CD8 + T cells, B cells, monocytes, natural killer (NK) T cells, and some dendritic cells (DCs) [1, 2] . Persistent expression of PD-1 on T cells induces T cell exhaustion [3] . Exhausted CD8 T cells lose their effector function, evidenced by their inability to secrete cytolytic molecules such as perforin and their failure to secrete proinflammatory cytokines, such as IL-2, interferon gamma (IFN-g), and tumor necrosis factor alpha (TNF-a) [4, 5] .
+ regulatory T cells (Tregs), a highly immunosuppressive subset of CD4 + T cells that is critical in maintaining tolerance and attenuating immune responses, express cell-surface PD-1, which contributes to their development, maintenance, and functional response [6] . Ligand binding to the PD-1 receptor on Tregs in the presence of CD3 and transforming growth factor beta (TGF-b) leads to an increase in the de novo conversion of naive CD4 + T cells to Tregs. This induction generates heightened suppressive function and maintenance of Foxp3 expression through inhibition of Akt-mammalian target of rapamycin (mTOR) signaling and increased phosphatase and tensin homolog (PTEN) activity [7, 8] . This indicates that PD-1 pathway stimulation results not only in a reduction in effector T cell function, but also an increase in immunosuppressive Treg function. This allows proper control of immune homeostasis and creates a high threshold for T cell activation.
Although PD-1 has best been characterized in T cells, its function in other cell subsets have also become apparent. The regulation of PD-1 expression is tightly controlled during B cell differentiation. Levels are undetectable in pro-B cells, an early precursor in B cell development, and increase as B cell differentiation [9] . Additionally, surface levels of PD-1 can be greatly enhanced in mature B cells following stimulation with Toll-like receptor 9 (TLR9) agonists. Blockade of PD-1 on B cells has been shown to increase antigen-specific antibody responses, suggesting that PD-1 plays a role in inhibiting B cell clonal responses [10] .
PD-1 has two binding ligands, PD-L1 (B7-H1, CD274) [11, 12] and PD-L2 (B7-DC, CD273) [13, 14] , with PD-L1 being the most prominent in regulation. PD-L1 is inducibly expressed on both hematopoietic cells and non-hematopoietic cells following cell-specific stimulation. Cytokines such as IFN-g and TNF-a upregulate the expression of PD-L1 on T cells, B cells, endothelial cells, and epithelial cells, furthering its role in the maintenance of peripheral tolerance [1] . Data also link genetic changes seen in cancer cells to the induction of PD-L1, although this can vary by cancer type. PTEN dysfunction in human glioma cells induces Akt activation and subsequently PD-L1 expression, while human melanoma cells show no association between PTEN or Akt and PD-L1 induction [15, 16] . Recent data show that PD-L1 binds to B7-1 (CD80) in addition to PD-1 [17] . While PD-L1 expression is induced on a wide array of both hematopoietic and non-hematopoietic cells, PD-L2 expression is restricted to inducible expression on DCs, macrophages, mast cells, and some B cells in response to IL-4 and IFN. The affinity of PD-L2 for PD-1 is three times greater than that of PD-L1, which indicates competition between the two ligands. Recent data confirm a second cognate receptor for PD-L2, repulsive guidance molecule B (RGMb) [18] . Despite recent research efforts surrounding PD-L2, little is known regarding the transcriptional regulation of the ligand.
Structures of PD-1 and its ligands
Structurally, PD-1 is a type I transmembrane receptor and belongs to the Ig superfamily (IgSF). Although it is functionally related to the costimulatory/coinhibitory receptors CD28, cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and inducible T cell costimulator (ICOS), PD-1 has important structural and functional differences. Other receptors in the CD28 family are disulfide-linked dimers; however, structural and cell-surface studies demonstrated that PD-1 is a monomeric glycoprotein [19] . The crystal structure of the extracellular region of mouse PD-1 shows the presence of a typical Ig variable domain (IgV) comprising front sheets (A'GFCC'C'') and back sheets (ABED) (Figure 1 ) stabilized by a disulfide bond linking the F and B strands [19] . This IgV domain is linked to transmembrane and cytoplasmic domains through a 20-amino acid stalk region. In contrast to other CD28 family receptors, the absence of an extracellular cysteine residue in the stalk region prevents PD-1 from covalent dimer formation.
Human and mouse PD-1 share around 60% overall identity at the protein level, which increases to 75% for the residues forming the IgV domain. It is unsurprising, therefore, that crystallographic [Protein Data Bank (PDB) code 3RRQ] and NMR structures [20] show a high degree of similarity between mouse and human PD-1. Overlay of the crystal structures of mouse and human PD-1 shows very similar arrangements (Figure 1 ). One notable difference between human and mouse PD-1 is the lack of the C'' strand at the edge of the front GFCC' sheet in human PD-1, as shown by the NMR data [20] . This region instead presents as a highly flexible loop, consistent with the poor electron density observed for that region in the crystallographic dataset, indicating a disordered arrangement (PBD code 3RRQ).
Another unique structural feature of PD-1 is that it lacks a consensus complementarity-determining region 3 (CDR3)-like conserved ligand-binding motif. The ligandbinding site comprises a hydrophobic patch on the front face contributed by multiple residues from several strands [19] . Crystal structures available for complexes of mouse PD-1 and human PD-L1 [21] and mouse PD-1 with mouse PD-L2 [22] show similar overall molecular architecture for these inhibitory complexes. Both PD-1 and its ligands interact with their respective surface residues distributed over their front beta sheets (front-to-front binding). By contrast, the FG loop of PD-1, which corresponds to the CDR3 variable region of the Ig structure, makes little or no contact with PD-L1 or PD-L2 (Figure 1 ). The crystal structures of the PD-1/PD-L complexes reveal that PD-1 binds its ligands with 1:1 stoichiometry and forms monomeric complexes. This indicates a distinct ligand-binding mode and signaling mechanism that differs from other coinhibitory receptor/ligand interactions such as CTLA-4/B7, where oligomerization plays an important role in signaling. Although crystal structures for the human PD-1/PD-L1 and PD-1/PD-L2 complexes remain to be solved, the overall similarity of the mouse and human PD-1 structures suggests that mouse and human PD-1 are likely to form similar complexes. Overlay of human PD-1 with the mouse complexes shows that human PD-1 may bind to its ligands in the same way as mouse PD-1; however, a recent study using NMR with binding data and mathematical modeling suggests that PD-1 may be engaged by its two ligands differently [20] .
Importantly, the available crystal structures of PD-1 and the PD-1/PD-L1 and PD-1/PD-L2 complexes allow not only mapping of the ligand-binding sites and mAb blocking epitopes, but also the design of small-molecule inhibitors. Prognostic relevance of PD-1 and its ligands in human malignancies Persistent expression of PD-1 by T cells is highly indicative of an exhausted phenotype, noted by a decrease in effector function [4, 5] . This phenotype has been observed in various types of tumor-infiltrating lymphocyte (TIL) and linked to poor prognosis and tumor recurrence, highlighting PD-1 as an important molecule in regulating antitumor activity (Table 1 ). Similar to PD-1, PD-L1 and PD-L2 also possess prognostic capacities in some human malignancies (Table 2) . Some clinical studies associate high expression of PD-L1 in tumors to tumor size, lymph node (LN) involvement, grade, and overall survival, while PD-L2 has generally been tied only to a trend in decreased survival that is not of statistical significance (Table 2) . PD-L1 generally has a much broader expression pattern compared with PD-L2. This indicates that the regulation of PD-L2 depends much more on environmental stimuli than that of PD-L1. Data from these studies provide a solid rationale for investigating the immunological mechanisms behind the clinical associations. The poor prognosis indicated by the expression of PD-1 on TILs and of PD-L1/2 on tumor cells supports the targeting of the pathway therapeutically.
Mechanisms of anti-PD-1 and anti-PD-L1 immunotherapy Appreciating the consequences of the upregulation of the PD-1/PD-L1/2 axis aids our progress in manipulating an immunosuppressive cancer microenvironment. The cytoplasmic tail of PD-1 contains two signaling motifs. One is an immunoreceptor tyrosine-based inhibitory motif (ITIM) and the other is an immunoreceptor tyrosine-based switch motif (ITSM). Binding of PD-L1 or PD-L2 to PD-1 on activated T cells, along with TCR signaling, leads to phosphorylation of the cytoplasmic domain tyrosines and recruitment of a Src homology 2-containing tyrosine phosphatase (SHP-2) to the ITSM. Consequently, SHP-2 dephosphorylates TCR-associated CD-3z and zeta chainassociated protein kinase 70 (ZAP70), resulting in inhibition of downstream signaling including blocking phosphoinositide 3-kinase (PI3K) and Akt activity, disrupting glucose metabolism and IL-2 secretion [5, 23] . mAbs have been developed for cancer immunotherapy by enhancing T cell function via blockade of the binding between PD-1 and PD-L1 or PD-L2 ( Figure 2 ). Many of these studies have shown that blockade of PD-1 alone or PD-L1 leads to an increase in T cells and IFN-g at the tumor site [24] , along with decreases in the percentages of the highly immunosuppressive myeloid-derived suppressor cell (MDSC) population [25] . Increase in the effector-tosuppressor cell ratio usually supports an antitumor microenvironment. These results demonstrate that the neutralization of PD-1, PD-L1, or PD-L2 can be effective in PD-L1 expression on monocytes in ascites and blood from patients with malignant ovarian carcinoma was greater than in those with borderline/benign disease; PD-L1 expression led to poorer prognosis and was inversely correlated with intraepithelial CD8 + T cells, while PD-L2 showed poorer prognosis but not a significant difference [68, 69] RCC Soluble PD-L1 was associated with larger tumors, worse stage, grade, and necrosis, and increased risk of death; PD-L1 was associated with poor prognosis [70, 71] HCC PD-L1 expression on hematoma cells enriched apoptotic CD8 + T cells; greater expression of PD-L1 was associated with significantly poorer prognosis and was an independent predictor for recurrence, while PD-L2 expression correlated with poorer survival but not recurrence [63, 72] NSCLC PD-L1 was associated with EGFR a mutations and was a negative prognostic factor [73] 
Melanoma
Greater PD-L1 expression correlated with significantly lower overall survival and vertical growth of primary tumors; PD-L1 marks a subset of melanomas with shorter overall patient survival [74, 75] Esophageal PD-L1 and PD-L2 expression led to significantly poorer prognosis while only PD-L2 expression was inversely correlated with CD8 + TILs [76] a Epidermal growth factor receptor.
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Trends in Molecular Medicine January 2015, Vol. 21, No. 1 controlling tumor growth by changing the dynamic of the tumor microenvironment. Additional approaches generating synergy are the blockade of PD-1 or PD-L1 in combination with other therapeutic agents. Simultaneous blockade of both PD-1 and CTLA-4 leads to expansion of TIL populations while reducing the number of MDSCs within the tumor, leading to tumor regression and significant increases in IFN-g and TNF-a in CD8 + T cells [26] . Furthermore, chemotherapy and radiotherapy are being studied in combination with the blockade of the PD-1/PD-L1 pathway [27, 28] . Together these results set the stage for an optimistic clinical outlook.
Various biological inhibitors of PD-1 and PD-L1 have been developed and are currently being tested in clinical trials with cancer patients (Table 3) . These inhibitors include mAbs to PD-1 and PD-L1 as well as PD-L2 fusion protein.
Clinical trials of mAbs to PD-1 Pidilizumab (CT-011) was the first mAb to PD-1 to reach clinical trials [29] (Table 4) . It was initially identified as a mAb binding to the B lymphoblastoid cell line that stimulated murine lymphocytes and showed antitumor activity in mice [30] . It stimulated human peripheral blood lymphocytes and enhanced cytotoxicity toward human tumor cell lines. The first Phase I trial with pidilizumab recruited patients with hematologic malignancies, including acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma (HL), and multiple myeloma (MM) [29] . Dose levels ranged from 0.2 to 6 mg/kg. A maximum tolerated dose (MTD) was not reached and the drug was well tolerated. Of the 17 patients enrolled in the study, one patient experienced a complete response, four had stable disease, and one had a mixed response, amounting to a 33% clinical benefit rate. Durable responses of greater than 60 weeks were The second Phase II study with pidilizumab was a combined treatment with rituximab for follicular lymphoma [31] . Patients with rituximab-sensitive disease were treated with four doses of pidilizumab at 3 mg/kg every 4 weeks, with the option to continue therapy if they showed a response or stable disease. The study enrolled 32 patients. Patients were fairly well distributed across the three risk groups of the Follicular Lymphoma International Prognostic Index (FLIPI) 1 and 2. The objective response rate was 66%, which met the study end point of greater than 60% compared with a historical response rate of 40% with rituximab alone. The complete response rate was 52%. Responses were durable, with a median PFS of 18.8 months. FLIPI 1 or 2 score was not associated with response rate. The regimen was well tolerated, with no grade 3 or 4 adverse events. PD-L1 expression was significantly higher on CD4 + , CD8 + , and CD14
+ peripheral blood cells from responding patients but was not associated with PFS. Gene expression data suggested that intrinsic antilymphoma immunity might be predictive of a response to pidilizumab. Pidilizumab continues to be evaluated in various clinical trials, including solid tumors and hematologic malignancies, both as a single agent and in combination with other regimens including cellular therapies and cancer vaccines.
Pembrolizumab (MK-3475; previously known as lambrolizumab) (Table 4) is a humanized IgG4 PD-1-blocking mAb [33, 34] . It is also the first mAb targeting PD-1 that has been granted accelerated FDA approval. A very highaffinity mouse antihuman PD-1 antibody was developed, the variable region of which was grafted to human IgG4 with a stabilizing S228P Fc mutation. The IgG4 subtype does not engage Fc receptors or activate complement, thus avoiding cytotoxic activity against T cells. Pembrolizumab was studied in a Phase I trial in patients with advanced solid tumors [33] . The dose range was 1-10 mg/kg and a MTD was not identified. In the nine patients enrolled in the study, no grade 3 or 4 toxicities were noted. One patient with melanoma experienced a partial response, with an additional three patients experiencing stable disease. Pembrolizumab activity and safety in melanoma was further explored by recruiting an expansion cohort at the 10 mg/kg dose level [34] . Doses ranged from 2 mg/kg every 3 weeks to 10 mg/kg every 2 weeks. Patients with advanced melanoma, including patients who had received prior treatment with ipilimumab, an FDA-approved mAb to CTLA-4, were allowed in this study. Results from 135 treated patients were reported. The response rate across all dose cohorts was 38%, with the highest response rate observed in the cohort given 10 mg/kg every 2 weeks (52%). Responses were durable and overall PFS was longer than 7 months. Median overall survival (OS) was not reached. Treatment-related grade 3 or 4 adverse events were reported in 13% of patients. The highest incidence of treatment-related adverse events was in the group given 10 mg/kg every 2 weeks. Endocrine toxicities included hypothyroidism in 8.1% of patients, with one case being grade 3 or 4, grade 3 hyperthyroidism, and grade 2 adrenal insufficiency. Correlative studies on available tumor biopsies showed that regressing lesions were densely infiltrated with cytotoxic T lymphocytes (CTLs), which was consistent with the mechanism of action of the drug. PD-L1 expression by tumor cells was significantly associated with PFS and response rate but not with OS [35] . It is important to note here that, despite a very low cut-off for PD-L1 positivity (1% of stained cells), antitumor activity was noted in tumors with low PD-L1 expression. These results cast doubt on the utility of PD-L1 expression as a biomarker and suggest that the mechanism of action of PD-1-targeting antibodies remains to be fully elucidated.
To explore the efficacy of pembrolizumab in malignant melanoma patients who had progressed after ipilimumab or treatment with a BRAF or mitogen-activated protein kinase kinase (MEK) inhibitor, or both, an open-label, randomized, multicenter expansion cohort of the KEY-NOTE-001 trial was performed [36] . The trial randomized 173 patients to receive pembrolizumab at 2 mg/kg or 10 mg/kg every 3 weeks. The overall response rate was 26% in both groups. Survival at 1 year was similar in the two treatment groups (58% and 63%). Pembrolizumab was well tolerated, with drug-related grade 3 or 4 adverse events reported in 12% of patients in both arms. Six patients (3%) discontinued treatment due to adverse events. Three patients experienced immune-related adverse events and were managed with dose interruption and corticosteroid treatment. Results from the KEYNOTE-001 trial served as the basis for the accelerated FDA approval of pembrolizumab for the treatment of patients with advanced or unresectable melanoma that progressed after therapy with ipilimumab or after therapy with a BRAF inhibitor in tumors carrying the BRAF V600 mutation. Of note in this trial is that the two dose levels exhibited similar antitumor activity and toxicity profiles. Pembrolizumab continues to be evaluated in Phase I trials in advanced solid tumors, head and neck cancers, and hematologic malignancies and in combination with lenalidomide and dexamethasone in relapsed/refractory MM, as well as in Phase II and III trials in microsatellite unstable tumors, in combination with pazopanib in renal cell cancer, and compared with docetaxel in NSCLC.
Nivolumab (MDX-1106, BMS-936558, ONO-4538) (Table 4 ) is a fully human IgG4 mAb to PD-1. In a humanized in vitro model of melanoma, addition of nivolumab to human vaccine-induced CD8 + T cells specific to melanoma antigens allowed the expansion of these lymphocytes [37] . In another study of an ex vivo melanoma model, addition of the same antibody led to the unmasking of CTL inhibition by Tregs and stimulated their proliferation [38] . Nivolumab was first studied clinically in a Phase I trial in patients with advanced solid tumors. Thirty-nine patients with metastatic melanoma, colorectal cancer (CRC), castrate-resistant prostate cancer (CRPC), NSCLC, or RCC were enrolled [39] . Initial treatment entailed a single infusion of nivolumab in doseescalating, six-patient cohorts at 0.3, 1, 3, or 10 mg/kg. This was followed by a 15-patient expansion cohort at the 10 mg/ kg level. Patients who had shown clinical benefit at 3 months were eligible for repeated therapy. MTD was not reached. One durable complete response of greater than 21 months was noted in a patient with CRC and two partial responses were noted in a patient with melanoma and another with RCC. Two additional responses were noted in one melanoma and one NSCLC patient, but did not meet partial response criteria. Tumor biopsies were available from a few patients and PD-L1 expression appeared to correlate with response to therapy. A cut-off of 5% of tumor cells exhibiting membranous PD-L1 staining was used to define positivity for PD-L1 expression. Nivolumab was well tolerated, with one patient experiencing grade 3 inflammatory colitis treated with infliximab and steroids.
Nivolumab was further studied in another large Phase I study [40] . Patients were treated with escalating doses ranging from 1 to 10 mg/kg. Analysis of 304 patients, including expansion cohorts, revealed that nivolumab was well tolerated, with no MTD reached. Objective response rates for melanoma, NSCLC, and RCC were 31%, 16%, and 29%, respectively. No responses were noted in patients with CRC or CRPC. Responses were durable and lasted over 1 year. Updated results indicate that responses are durable in patients with NSCLC, with OS rates of 12-45% at 2 years [41] . Similarly, 2-and 3-year OS rates in patients with advanced melanoma were 48% and 41%, respectively [42] . Examination of PD-L1 expression revealed that responses were noted only in PD-L1-positive tumors (36%). Again, a cut-off of 5% of tumor cells staining positive for membranous PD-L1 expression by immunohistochemistry was used to define positivity. Grade 3 or 4 adverse events were noted in 15% of patients and 6% discontinued treatment. Adverse events with potentially immune-related etiology occurred in 45% of patients, being grade 3 or 4 in 6% of these. Three deaths due to pneumonitis were reported. Other studies of nivolumab have reported similar results, as detailed in Table 4 .
Nivolumab was also studied in combination with ipilimumab in a Phase I trial [43] . The trial included a combined-regimen arm that enrolled 53 patients and a sequenced-regimen arm that enrolled 33. The MTD was determined to be at the 1 mg/kg nivolumab and 3 mg/kg ipilimumab dose level (cohort 2) and at 3 mg/kg for nivolumab and 1 mg/kg for ipilimumab (cohort 2a) in the combined regimen. Response rates were 40% in the combined regimen group and up to 53% in the MTD cohort. Complete responses were noted as well as 80% tumor reduction in 16 patients. Responses were durable, ranging from 6.1 to 72.1 weeks at the time of analysis. Treatmentrelated grade 3 or 4 adverse events were observed in 53% of patients and serious adverse events were reported in 49% of patients in the combined-regimen group; 21% of patients discontinued therapy due to adverse events. Adverse events were managed with immune suppressants, some requiring infliximab or mycophenolate mofetil. No Clinical trials of mAbs to PD-L1 BMS-936559 is a fully human monoclonal IgG4 antibody that blocks PD-L1 [44] (Table 4) . This blockade was shown to augment T cell proliferation in response to allogeneic dendritic cells in a mixed lymphocyte reaction, as well as antigen-specific T cell responses to cytomegalovirus (CMV) antigen and antitumor peptide responses in subjects treated with melanoma antigen peptide vaccines. BMS-936559 can reverse in vitro Treg-mediated suppression. Use of BMS-936559 in clinical trials was supported by the ability of anti-PD-L1 antibodies to inhibit tumor growth in murine syngeneic tumor models and long-lived antitumor immunity was observed. BMS-936559 did not induce antibody-dependent cytotoxicity or complement-dependent cytotoxicity in PD-L1-positive cells. BMS-936559 was studied in a Phase I trial [44] . Patients with various solid tumors were enrolled, with disease-specific expansion cohorts enrolled in parallel and treated at the 10 mg/kg dose level. MTD was not reached and the discontinuation rate due to adverse events was 11%, 6% of which were treatment related. Objective responses were observed in patients treated with a dose of 1 mg/kg or higher. Responses were noted in patients with melanoma, NSCLC, RCC, or ovarian cancer but none were observed in CRC or pancreatic cancer. Treatment was well tolerated with the expected immune-related adverse events, which were mostly grade 1 or 2 and were managed by interruption of treatment or with glucocorticoids. Despite encouraging results, BMS-936559 does not seem to have been developed any further by the manufacturer.
MEDI4736 is a humanized PD-L1-blocking mAb [45] that showed T cell-dependent antitumor activity in an in vivo model where tumor cells were coimplanted with human T cells or when a surrogate antibody was used in a syngeneic mouse model (Table 4) . Combination with oxaliplatin resulted in complete tumor regression in greater than 50% of treated animals. MEDI4736 is being studied in a Phase I trial in advanced solid tumors with expansion cohorts in several responding tumor types including NSCLC and melanoma [46, 47] . It was noted to be well tolerated, with tumor shrinkage detectable in many tumor types. It is also being studied in combination with tremelimumab (a mAb to CTLA-4) in patients with advanced solid tumors [48] and with dabrafenib and trametinib or trametinib alone in patients with malignant melanoma.
Other mAbs to PD-L1 include MPDL3280A, which has shown impressive results shrinking tumors in 43% of patients in a Phase I clinical trial in metastatic urothelial bladder cancer [49] (http://www.roche.com/media/media_r-eleases/med-cor-2014-05-31.htm) ( Table 4) . It has been granted FDA breakthrough designation due to its activity in urothelial bladder cancers. It has also shown acceptable tolerability and efficacy in several solid tumors, with no MTD reached [50] . Ongoing clinical trials include Phase I trials in advanced solid tumors and the phase II BIRCH trial and phase III OAK trial in NSCLC. MSB0010718C is another mAb to PD-L1. It is a fully human IgG1 and is expected to show antineoplastic activity by inhibiting the PD-1/PD-L1 interaction and by antibody-dependent cellmediated cytotoxicity [51] . MSB0010718C is being studied in a Phase I trial in refractory malignancies.
Clinical trials of PD-L2 Ig fusion protein
As an alternative strategy to mAbs, AMP-224 (B7-DC-Ig) was developed as a chimeric fusion protein between the extracellular domain of PD-L2 and an Fc portion of IgG2a (http://www.prnewswire.com/news-releases/glaxosmithkline-and-amplimmune-form-global-strategic-collaboration-99938599.html). In vivo studies suggested that this fusion protein can ameliorate disease by inducing immune responses to pathogens. Furthermore, the murine form of AMP-224 can enhance the therapeutic efficacy of vaccination when combined with cyclophosphamide in a mouse model [52] . AMP-224 exerts its therapeutic effect via a mechanism distinct from the direct blocking of the PD-1/ PD-L1 interaction. It is hypothesized that AMP-224 can deplete exhausted effector T cells that express high levels of PD-1 and the T cell pool is replenished with functional T cells [53] . Ongoing trials with AMP-224 include a Phase I trial with cyclophosphamide in advanced solid tumors that has shown no drug-related inflammatory adverse events other than infusion reactions, as well as preliminary tumor responses [53] .
Concluding remarks
After success with ipilimumab in the treatment of malignant melanoma, the field of cancer immunotherapy continues to grow. Blockade of T cell inhibition allows restored antitumor immunity and has shown impressive results in clinical trials. Beyond the CTLA-4 pathway, T cell inhibition mediated by the PD-1/PD-L1 pathway is now the most studied and clinically developed cancer immunotherapy. Several mAbs to PD-1 or PD-L1 have been studied in Phase I trials and continue to be evaluated in Phase II and Phase III trials. These therapies have been well tolerated, with no MTD reached in most single-agent Phase I studies. Grade 3 or 4 adverse event rates have been generally acceptable, with low treatment-related discontinuation rates. Response rates have been impressive, particularly in melanoma, NSCLC, and RCC, with encouraging early reports from urothelial bladder cancer and platinum-resistant ovarian cancer. PD-1/PD-L1 blockade has also shown efficacy in hematologic malignancies. What has been striking is the durability of responses. Potential biomarkers for efficacy of PD-1/PD-L1 blockade are being studied, to date mainly focusing on PD-L1 expression by the tumor. The data from most clinical studies are not yet mature, but preliminary data indicate that PD-L1 expression by tumor cells may correlate with higher response rate and PFS in some patients. It is encouraging that pembrolizumab has been granted accelerated FDA approval as second-line therapy in advanced melanoma. Integrating immunotherapy into current clinical practice remains to be studied and many outstanding questions remain (Box 1). The variability in response both by tumor subtype and by PD-L1 expression indicates that immune checkpoint inhibition remains a field that is open to study and that PD-1/PD-L1 blockade, like CTLA4 blockade before it, is only the beginning of immunomodulatory therapies. 
